Role of colectomy in the management of appendiceal tumors: a retrospective cohort study.
Appendectomy
Appendiceal neoplasms
Appendix
Hemicolectomy
Survival analysis
Journal
BMC gastroenterology
ISSN: 1471-230X
Titre abrégé: BMC Gastroenterol
Pays: England
ID NLM: 100968547
Informations de publication
Date de publication:
17 Nov 2023
17 Nov 2023
Historique:
received:
11
07
2023
accepted:
29
10
2023
medline:
20
11
2023
pubmed:
18
11
2023
entrez:
18
11
2023
Statut:
epublish
Résumé
Appendiceal tumors represent a range of histologies that vary in behavior. Recommendations for treatment with appendectomy versus right hemicolectomy (RHC) for different tumor types are evolving and sometimes conflicting. This study sought to characterize variation in the United States around surgical treatment of major appendiceal tumor types over time and describe differences in outcomes based on procedure. Patients diagnosed with appendiceal goblet cell adenocarcinoma (GCA), mucinous adenocarcinoma, neuroendocrine neoplasm (NEN), or non-mucinous adenocarcinoma from 2004-2017 were identified in the National Cancer Database. Trends in RHC over time and predictors of RHC were identified. Surgical outcomes for each histologic type and stage were compared. Of 18,216 patients, 11% had GCAs, 34% mucinous adenocarcinoma, 31% NENs, and 24% non-mucinous adenocarcinoma. Rate of RHC for NEN decreased from 68% in 2004 to 40% in 2017 (p = 0.008) but remained constant around 60-75% for other tumor types. Higher stage was associated with increased odds of RHC for all tumor types. RHC was associated with higher rate of unplanned readmission (5% vs. 3%, p < 0.001) and longer postoperative hospital stay (median 5 days vs. 3 days, p < 0.001). On risk-adjusted analysis, RHC was significantly associated with increased survival versus appendectomy for stage 2 disease of all tumor types (HRs 0.43 to 0.63) and for stage 1 non-mucinous adenocarcinoma (HR = 0.56). Most patients with appendiceal tumors undergo RHC, which is associated with increased readmission, longer length of stay, and improved survival for stage 2 disease of all types. RHC should be offered selectively for appendiceal tumors.
Sections du résumé
BACKGROUND
BACKGROUND
Appendiceal tumors represent a range of histologies that vary in behavior. Recommendations for treatment with appendectomy versus right hemicolectomy (RHC) for different tumor types are evolving and sometimes conflicting. This study sought to characterize variation in the United States around surgical treatment of major appendiceal tumor types over time and describe differences in outcomes based on procedure.
METHODS
METHODS
Patients diagnosed with appendiceal goblet cell adenocarcinoma (GCA), mucinous adenocarcinoma, neuroendocrine neoplasm (NEN), or non-mucinous adenocarcinoma from 2004-2017 were identified in the National Cancer Database. Trends in RHC over time and predictors of RHC were identified. Surgical outcomes for each histologic type and stage were compared.
RESULTS
RESULTS
Of 18,216 patients, 11% had GCAs, 34% mucinous adenocarcinoma, 31% NENs, and 24% non-mucinous adenocarcinoma. Rate of RHC for NEN decreased from 68% in 2004 to 40% in 2017 (p = 0.008) but remained constant around 60-75% for other tumor types. Higher stage was associated with increased odds of RHC for all tumor types. RHC was associated with higher rate of unplanned readmission (5% vs. 3%, p < 0.001) and longer postoperative hospital stay (median 5 days vs. 3 days, p < 0.001). On risk-adjusted analysis, RHC was significantly associated with increased survival versus appendectomy for stage 2 disease of all tumor types (HRs 0.43 to 0.63) and for stage 1 non-mucinous adenocarcinoma (HR = 0.56).
CONCLUSIONS
CONCLUSIONS
Most patients with appendiceal tumors undergo RHC, which is associated with increased readmission, longer length of stay, and improved survival for stage 2 disease of all types. RHC should be offered selectively for appendiceal tumors.
Identifiants
pubmed: 37978348
doi: 10.1186/s12876-023-03019-4
pii: 10.1186/s12876-023-03019-4
pmc: PMC10655451
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
398Informations de copyright
© 2023. The Author(s).
Références
J Gastrointest Surg. 2015 Apr;19(4):743-50
pubmed: 25560182
Br J Surg. 2004 Mar;91(3):304-11
pubmed: 14991630
Int J Surg Pathol. 2019 Apr;27(2):142-146
pubmed: 30021480
J Am Coll Surg. 2019 Jun;228(6):839-851
pubmed: 30898583
J Surg Oncol. 2006 Oct 1;94(5):396-402
pubmed: 16967437
Ann Surg. 2010 Apr;251(4):659-69
pubmed: 20224370
Am Surg. 2004 Jul;70(7):593-9
pubmed: 15279181
World J Surg. 2005 Nov;29(11):1436-9
pubmed: 16136284
World J Surg Oncol. 2005 Jun 20;3:36
pubmed: 15967038
Ann Surg Oncol. 2012 May;19(5):1379-85
pubmed: 22302267
Am Soc Clin Oncol Educ Book. 2021 Mar;41:1-15
pubmed: 33770459
J Surg Res. 2019 Jun;238:198-206
pubmed: 30772678
JCO Oncol Pract. 2021 Jan;17(1):e1-e10
pubmed: 33270520
J Surg Oncol. 2019 Dec;120(7):1096-1101
pubmed: 31592538
Neuroendocrinology. 2016;103(2):144-52
pubmed: 26730583
Ann Surg Oncol. 2006 Mar;13(3):370-6
pubmed: 16485156
Radiographics. 2017 Jul-Aug;37(4):1059-1083
pubmed: 28598731
Pancreas. 2010 Aug;39(6):753-66
pubmed: 20664473
J Surg Oncol. 2020 Nov;122(6):1173-1178
pubmed: 32638405
J Am Coll Surg. 2015 May;220(5):894-903
pubmed: 25840530
Cancer. 2020 Mar 1;126(5):1068-1076
pubmed: 31702829
Surg Oncol. 2015 Mar;24(1):47-53
pubmed: 25686643
JAMA Oncol. 2017 Dec 1;3(12):1722-1728
pubmed: 28241198
Histopathology. 2017 Dec;71(6):847-858
pubmed: 28746986
Acta Gastroenterol Belg. 2020 Jul-Sep;83(3):441-448
pubmed: 33094592
Dis Colon Rectum. 2019 Dec;62(12):1425-1438
pubmed: 31725580
J Surg Oncol. 2019 Sep;120(3):446-451
pubmed: 31236958
Lancet Oncol. 2023 Feb;24(2):187-194
pubmed: 36640790
Ann Surg Oncol. 2013 Apr;20(4):1063-7
pubmed: 23456377
J Surg Oncol. 2020 Sep;122(3):399-406
pubmed: 32346885
Ann Surg Oncol. 2021 Dec;28(13):8916-8925
pubmed: 34409541
Neuroendocrinology. 2018;106(3):242-251
pubmed: 28641291